CARDINAL HEALTH’S LEADERSHIP IN DEVELOPING THE CIRCULAR HEALTHCARE ECONOMY IN AUSTRALIAN MEDICAL DEVICES
With
Neroli Manning,
Managing Director
Cardinal Health – Australia & New Zealand
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | May 2026
Neroli Manning is the Managing Director for Cardinal Health Australia & New Zealand (ANZ). With over 30 years of experience in the healthcare industry, Neroli is a transformative leader known for her people-first, customer-centric leadership style.
Her career spans Australia, New Zealand, and the Asia Pacific region, where she has held senior management roles in the medical device, capital equipment, and radiopharmaceutical sectors with global leaders like CR Bard, Medtronic, Philips, Abbott, and Sirtex.
Neroli’s leadership is defined by her ability to drive change, foster collaboration, and build high-performing teams. Additionally, having held a variety of senior commercial functional positions, she is able to leverage her deep experience and cross-functional insights to align teams, streamline operations, and deliver strategic outcomes. She is also passionate about mentoring emerging leaders and shaping the future of healthcare through inclusive, values-driven leadership.
As a founder of her own healthcare consulting firm, Neroli demonstrated entrepreneurial leadership, guiding global medical device companies through complex market challenges. Her legacy includes cultivating cultures of accountability, innovation, and continuous learning.
Beyond leading Cardinal Health’s operations in ANZ, Neroli also contributes to the broader industry as a company director and member of the Industry Policy Committee for the Medical Technology Association of Australia (MTAA).
Neroli has a Master’s of Business (Marketing) degree from the University of Technology, Sydney. In her spare time, she enjoys spending time with friends and family, exercising, working on her farm, travelling and playing golf.
Source: Supplied
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Changes in MBS bulk billing incentives address GP capacity in women’s health
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
-
World-first clinical trial improves patient outcomes for kidney transplants
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.
